Last update 20 Mar 2025

Murlentamab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-AMHR2 monoclonal antibody, Anti-MISRII humanised monoclonal antibody 3C23K, Anti-mullerian human receptor-II monoclonal antibody
+ [5]
Target
Action
antagonists
Mechanism
AMHR2 antagonists(Anti-Mullerian hormone receptor II antagonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 2
Belgium
11 Jul 2018
Colorectal CancerPhase 2
Czechia
11 Jul 2018
Female Genital NeoplasmsPhase 2
Belgium
01 Jun 2016
Female Genital NeoplasmsPhase 2
France
01 Jun 2016
Female Genital NeoplasmsPhase 2
United Kingdom
01 Jun 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Neoplasms
AMHRII
68
(ueckfttvhl) = Most common toxicity was G1-2 asthenia (29 %). dhryqmbvpw (jlrzzbvfgl )
Positive
01 Jun 2019
Paclitaxel+carboplatin+Murlentamab
Phase 1
27
oinenbrfgr(duvzfuttrd) = One pt had grade 3 anorexia and weight loss zbffgdwfoq (nooiszylcj )
Positive
01 Jun 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free